From Clinical Data to Real-World Outcomes

Gene therapies are measured in data points, enzyme levels, scan results, and longitudinal follow-up intervals. But every number in a clinical trial has a name behind it.

For decades, the Canavan community has lived in the gap between the science that was possible and supportive care. That gap is now closing. And for one family in Ireland, it closed in a way that no clinical chart can fully capture. It was the sound of their child’s laughter, heard for the first time weeks after receiving MYR-101.

At Myrtelle, we have never lost sight of what the numbers represent. This is the story of what it looks like when science catches up.

Among the Youngest to Receive MYR-101

In early 2026, an Irish baby, approximately five months old at the time of treatment, became one of the youngest in the world to receive MYR-101, Myrtelle’s rAAV-Olig001-ASPA gene therapy candidate currently in Phase 1/2 clinical trials.

The procedure was performed at Dayton Children’s Hospital, where neurosurgeon Dr. Rob Lober delivered the therapy via catheter directly into the brain. Every step of the protocol was conducted under the scientific direction of Professor Paola Leone. Her foundational research into oligodendrocyte targeting made the development of MYR-101 possible, and her 25 years of expertise in neurogenetic gene therapies guided the team through each stage of treatment.

What happened next is what this community has been building toward. Within weeks, the family observed increased alertness, laughter, and follow-up imaging showed reduced brain swelling – early clinical signals that support MYR-101’s mechanism of action is working as intended to produce observable changes after treatment.

MYR-101 Program Milestones

This clinical signal does not exist in isolation. It is the product of years of rigorous science, regulatory positioning, and community partnership. Here is where Myrtelle stands:

Nature Medicine Publication (September 2025): Our landmark peer-reviewed study confirmed that MYR-101 restored myelin and reduced toxic NAA levels in treated children, the scientific foundation for every clinical outcome we are now observing in trial participants.

Phase 1/2 Clinical Trial (Ongoing): MYR-101 has demonstrated a favorable safety profile with no serious adverse events related to the drug itself. Each enrolled participant expands the longitudinal dataset that will support our BLA submission.

FDA START Pilot Program: Myrtelle is one of seven companies and one of three gene therapies selected for this program, maintaining direct, ongoing FDA communication and a streamlined pathway for MYR-101’s commercial development.

RMAT Designation: Our Regenerative Medicine Advanced Therapy designation positions MYR-101 for rolling review, priority review, and accelerated approval at the time of BLA submission.

Dayton Children’s Hospital: The site continues to serve as the center of clinical excellence for MYR-101administration, with Dr. Lober and Prof. Leone’s collaboration defining how this treatment is delivered.

The Biology Behind the Early Outcomes

MYR-101 delivers a functional copy of the ASPA gene directly into oligodendrocytes, the cells responsible for producing and maintaining the myelin the brain requires for neurological function. In Canavan disease, a mutated ASPA gene disrupts the enzyme pathway, causing N-acetylaspartate to accumulate at toxic levels. This accumulation damages myelin. Without it, the very functions families fight for, such as movement, alertness, and responsiveness, cannot develop. When this child became more alert weeks after treatment, it was a potential sign of their biology responding to the intervention.

The reduced brain swelling observed on imaging is consistent with precisely what the Nature Medicine publication reported in September 2025: that MYR-101 restores myelin and reduces toxic NAA levels in treated children.

By having the new genetic capability to create ASPA, NAA can be properly broken down into the materials that are critical to manufacture myelin, allowing neurological development to resume. The family’s observations and the imaging data tell the same story.

 

ASGCT 2026: When the Field Sees the Data

The American Society of Gene & Cell Therapy annual conference is where the broader scientific and clinical community encountered these early outcomes in a formal context.

Prof. Leone presented long-term follow-up data from the Phase 1/2 trial of MYR-101 at ASGCT 2026, including safety data, durable efficacy signals, and the emerging early outcomes from treated children. This presentation formed part of the clinical record supporting Myrtelle’s path toward BLA submission.

The regulatory path ahead is not without complexity, no BLA process ever is but the signals are pointing in the right direction.

 

How to Be Part of This Moment

The clinical outcomes now emerging belong to this entire community. Every family who advocated, every researcher who published, every organization that funded early-stage work contributed to the moment a family saw their child do something they hadn’t done before in the weeks after receiving MYR-101.

Share the Science: The Nature Medicine publication and Myrtelle’s Phase 1/2 results are public record. Share them. When science reaches more people, it reaches more policymakers, more clinicians, and more families who don’t yet know a treatment for Canavan is being developed.

Support the Organizations Behind the Families: The Cure Canavan Fund, the Canavan Foundation, and NTSAD provide the grassroots infrastructure: family support, early research funding, patient advocacy.